K-V Pharmaceutical Co. Monday unveiled a bankruptcy-exit plan that hinges on a $20 million rights offering and has already earned the support of a group of senior noteholders.

Following K-V Pharma’s recent filing for bankruptcy, Daniel Ghinn takes a look at the part social media played and shares his thoughts on just how important it is for pharma companies to have a ...

CHAPTER 11: K-V Pharmaceutical Co. filed for Chapter 11 bankruptcy protection Saturday, saying weak sales of its preterm birth drug Makena and regulatory sanctions are hurting its business ...

Fintel reports that on June 17, 2025, Citigroup initiated coverage of NewAmsterdam Pharma Company N.V. (NasdaqGM:NAMS) with a Buy recommendation. Analyst Price Forecast Suggests 126.67% Upside As of ...